echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The symptoms of infection in the new coronary variant are mild or provide clues to research and development of drugs, etc

    The symptoms of infection in the new coronary variant are mild or provide clues to research and development of drugs, etc

    • Last Update: 2020-12-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    LONDON, Aug. 21 (Xinhua Zhang Jiawei) A Singapore research team recently published a report in the British Lancet, said that patients infected with a less common new coronavirus variant after the symptoms are relatively light, in-depth understanding of the structure of this variant may provide clues to new coronary therapy and vaccine research and development.
    from Singapore's National Centre for Infectious Diseases and others compared the new coronavirus variant, which appeared in the country from 22 January to 21 March in other countries. The study covered 131 new coronavirus infection patients, 92 of whom were infected with the original new coronavirus, 29 with the virus variant, and 10 with both the original coronavirus and the virus variant.
    analysis showed that people infected with the virus variant had lighter symptoms than those infected with the original virus. None of the 29 people in the variant infection group experienced hypoxia or needed auxiliary oxygen supply, while 26 of the 92 people in the original viral infection group experienced hypoxia.
    researchers say the variant's genome is missing 382 nucleotides in a protein-coded region called ORF8, a deficiency that may be associated with relatively mild clinical symptoms after a patient has been infected with a viral variant, but more research is needed to confirm this. The results may deepen the medical community's understanding of the virology of the new coronavirus and provide clues to the search for treatments and vaccine research and development.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.